8-K 1 v176880_8k.htm
SECURITIES AND EXCHANGE COMMISSION 
WASHINGTON, D.C. 20549 
 
FORM 8-K 
 
CURRENT REPORT 
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 
 
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED)
March 10, 2010
 
NOVELOS THERAPEUTICS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)
         
DELAWARE
  
333-119366
  
04-3321804
(STATE OR OTHER JURISDICTION
  
(COMMISSION
  
(IRS EMPLOYER
OF INCORPORATION)
  
FILE NUMBER)
  
IDENTIFICATION NO.)
 
One Gateway Center, Suite 504, Newton, Massachusetts 02458
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
 
REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE: (617) 244-1616
 
NOT APPLICABLE
(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)
 
CHECK THE APPROPRIATE BOX BELOW IF THE FORM 8-K FILING IS INTENDED TO SIMULTANEOUSLY SATISFY THE FILING OBLIGATION OF THE REGISTRANT UNDER ANY OF THE FOLLOWING PROVISIONS:
 
o
  
WRITTEN COMMUNICATIONS PURSUANT TO RULE 425 UNDER THE SECURITIES ACT (17 CFR 230.425)
     
o
  
SOLICITING MATERIAL PURSUANT TO RULE 14a-12 UNDER THE EXCHANGE ACT (17 CFR 240.14a-12)
     
o
  
PRE-COMMENCEMENT COMMUNICATIONS PURSUANT TO RULE 14d-2(b) UNDER THE EXCHANGE ACT (17 CFR 240.14d-2(b))
     
o
  
PRE-COMMENCEMENT COMMUNICATIONS PURSUANT TO RULE 13e-4(c) UNDER THE EXCHANGE ACT (17 CFR 240.13e-4(c))

 
 
 
 
ITEM 7.01 REGULATION FD DISCLOSURE  
 
A copy of the press release issued by us on March 10, 2010 relating to the filing of a purported class action complaint against Novelos and Harry S. Palmin, our President and Chief Executive Officer, is furnished as Exhibit 99.1 and is incorporated by reference in this Item.  The complaint alleges that Novelos and Harry S. Palmin violated Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
 
ITEM 9.01  FINANCIAL STATEMENTS AND EXHIBITS  

(c) Exhibits
 
Number
  
Title
     
99.1
  
Press Release dated March 10, 2010 entitled “Novelos Therapeutics Believes Class Action Lawsuit is Without Merit and Intends to Defend Vigorously”

 
- 2 -
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
 Dated: March 10, 2010
NOVELOS THERAPEUTICS, INC.
 
  
 
By:  
/s/ Harry S. Palmin  
  
   
Harry S. Palmin
  
   
President and Chief Executive Officer
  

 
- 3 -
 
 
EXHIBIT INDEX
 
Number
  
Title
     
99.1
  
Press Release dated March 10, 2010 entitled “Novelos Therapeutics Believes Class Action Lawsuit is Without Merit and Intends to Defend Vigorously”
 
 
- 4 -